RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adaptimmune Therapeutics Stock

Adaptimmune Therapeutics Net Income 2024

Adaptimmune Therapeutics Net Income

-713.71 M USD

Ticker

ADAP

ISIN

US00653A1079

WKN

A14SUX

In 2024, Adaptimmune Therapeutics's profit amounted to -713.71 M USD, a 526.77% increase from the -113.87 M USD profit recorded in the previous year.

The Adaptimmune Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2029e1.61
2028e-0.92
2027e-1.25
2026e-0.75
2025e-0.67
2024e-0.71
2023-0.11
2022-0.17
2021-0.16
2020-0.13
2019-0.14
2018-0.1
2017-0.07
2016-0.07
2015-0.02
2014-0.01
2013-0.01
2012-0.01

Adaptimmune Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Adaptimmune Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Adaptimmune Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Adaptimmune Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Adaptimmune Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Adaptimmune Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Adaptimmune Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Adaptimmune Therapeutics’s growth potential.

Adaptimmune Therapeutics Revenue, EBIT and net profit per share

DateAdaptimmune Therapeutics RevenueAdaptimmune Therapeutics EBITAdaptimmune Therapeutics Net Income
2029e296.21 M undefined259.49 M undefined1.61 B undefined
2028e194.48 M undefined-96.05 M undefined-923.44 M undefined
2027e122.5 M undefined-142.36 M undefined-1.25 B undefined
2026e86.85 M undefined-187.73 M undefined-751.28 M undefined
2025e46.28 M undefined-170.22 M undefined-669.62 M undefined
2024e164.09 M undefined-171.02 M undefined-713.71 M undefined
202360.28 M undefined-130.69 M undefined-113.87 M undefined
202227.15 M undefined-161.67 M undefined-165.46 M undefined
20216.15 M undefined-162.25 M undefined-158.09 M undefined
20203.96 M undefined-133.41 M undefined-130.09 M undefined
20191.12 M undefined-139.77 M undefined-137.17 M undefined
201859.51 M undefined-82.37 M undefined-95.51 M undefined
201737.83 M undefined-80.66 M undefined-70.14 M undefined
201614.2 M undefined-72.8 M undefined-71.58 M undefined
201510.72 M undefined-23.07 M undefined-21.59 M undefined
2014580,000 undefined-13.71 M undefined-12.12 M undefined
20130 undefined-9.64 M undefined-8.73 M undefined
20120 undefined-9.64 M undefined-8.73 M undefined

Adaptimmune Therapeutics stock margins

The Adaptimmune Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Adaptimmune Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Adaptimmune Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Adaptimmune Therapeutics's sales revenue. A higher gross margin percentage indicates that the Adaptimmune Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Adaptimmune Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Adaptimmune Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Adaptimmune Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Adaptimmune Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Adaptimmune Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Adaptimmune Therapeutics Margin History

Adaptimmune Therapeutics Gross marginAdaptimmune Therapeutics Profit marginAdaptimmune Therapeutics EBIT marginAdaptimmune Therapeutics Profit margin
2029e0 %87.6 %544.25 %
2028e0 %-49.39 %-474.83 %
2027e0 %-116.21 %-1,022.14 %
2026e0 %-216.15 %-865.02 %
2025e0 %-367.82 %-1,446.96 %
2024e0 %-104.22 %-434.95 %
20230 %-216.8 %-188.9 %
20220 %-595.47 %-609.43 %
20210 %-2,638.21 %-2,570.57 %
20200 %-3,368.94 %-3,285.1 %
20190 %-12,479.47 %-12,247.32 %
20180 %-138.41 %-160.49 %
20170 %-213.22 %-185.41 %
20160 %-512.68 %-504.08 %
20150 %-215.21 %-201.4 %
20140 %-2,363.79 %-2,089.66 %
20130 %0 %0 %
20120 %0 %0 %

Adaptimmune Therapeutics Aktienanalyse

What does Adaptimmune Therapeutics do?

Adaptimmune Therapeutics PLC is a biotechnology company specializing in the development of immunotherapies against cancer. The company was founded in 2008 and is headquartered in Oxfordshire, England. Adaptimmune focuses on harnessing the human immune system to target and destroy cancer cells. The company's business model primarily revolves around the research and development of therapeutic products for different types of cancer. It develops and utilizes T-cell receptor (TCR) therapies to specifically target cancer cells. TCRs are proteins on T-cells that can recognize and kill cancer cells. Adaptimmune harnesses this property of TCRs to develop specific receptors targeted against certain types of cancer. Adaptimmune has three different business segments: oncology, autoimmune diseases, and infections. However, the focus is primarily on oncology. In this area, Adaptimmune concentrates on developing TCR products for various types of cancer such as pancreatic cancer, esophageal cancer, and lung cancer. One of Adaptimmune's key products is the T-cell therapy known as SPEAR (Specific Peptide Enhanced Affinity Receptor), which is individually developed for each patient. This therapy utilizes TCRs targeting specific tumor cells. The TCRs are optimized so that the body's own T-cells can precisely recognize and destroy the cancer cells. SPEAR has already shown promising results in a clinical study for melanoma patients. Another important product of Adaptimmune is ADP-A2M4. This immunotherapy also utilizes TCRs developed to target specific cancer cells. ADP-A2M4 is currently in Phase II clinical trials for advanced or metastatic esophageal cancer or gastric cancer. Adaptimmune also has partnerships with other companies and organizations such as GSK, NY-ESO-1, Universal Cells, and the MD Anderson Cancer Center. This collaboration expands the company's portfolio and enables the development of innovative immunotherapies. Overall, Adaptimmune's goal is to develop innovative TCR products for the treatment of various types of cancer. With its focus on immunotherapies, the company has created unique solutions to mobilize the human immune system specifically against cancer. Adaptimmune has the potential to revolutionize cancer treatment and improve the lives of millions of people. Adaptimmune Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Adaptimmune Therapeutics's Profit Margins

The profit margins of Adaptimmune Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Adaptimmune Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Adaptimmune Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Adaptimmune Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Adaptimmune Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Adaptimmune Therapeutics stock

How much profit has Adaptimmune Therapeutics made this year?

Adaptimmune Therapeutics has made -713.71 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 526.77% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Adaptimmune Therapeutics publish its earnings?

Adaptimmune Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Adaptimmune Therapeutics?

The profits of Adaptimmune Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Adaptimmune Therapeutics?

You can learn more about the earnings of Adaptimmune Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Adaptimmune Therapeutics pay?

Over the past 12 months, Adaptimmune Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adaptimmune Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Adaptimmune Therapeutics?

The current dividend yield of Adaptimmune Therapeutics is .

When does Adaptimmune Therapeutics pay dividends?

Adaptimmune Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adaptimmune Therapeutics?

Adaptimmune Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Adaptimmune Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adaptimmune Therapeutics located?

Adaptimmune Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adaptimmune Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adaptimmune Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Adaptimmune Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Adaptimmune Therapeutics in the year 2023?

In the year 2023, Adaptimmune Therapeutics distributed 0 USD as dividends.

In which currency does Adaptimmune Therapeutics pay out the dividend?

The dividends of Adaptimmune Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Adaptimmune Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Adaptimmune Therapeutics

Our stock analysis for Adaptimmune Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adaptimmune Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.